New state of the art bottling plant for Lucozade and Ribena
GlaxoSmithKline (GSK) Consumer Healthcare has announced a further £18m investment in their manufacturing facility at Coleford, Gloucestershire. The investment is for a new high speed, high efficiency bottling plant which will manufacture a range of Lucozade and Ribena products using state of the art technology.
GlaxoSmithKline (GSK) Consumer Healthcare has announced a further £18m investment in their manufacturing facility at Coleford, Gloucestershire. The investment is for a new high speed, high efficiency bottling plant which will manufacture a range of Lucozade and Ribena products using state of the art technology.
This added capacity will improve cost efficiency by enabling GSK’s supply chain to be minutely responsive to customer demand and removing the need to maintain costly stocks of product. The new line uses recycled plastic PET bottles which are manufactured at Coleford and will also include the capability to produce a range of new multipack products.
In 2011 a new £70m bottle manufacturing plant was opened at Coleford – one of the largest in-house bottle manufacturing operations in Europe. This was GSK Consumer Healthcare’s largest capital expenditure to date and has already delivered significant cost savings in terms of reduced transportation costs, reduced plastic use and reduced energy expenditure – for example, costs associated with transporting plastic bottles have been reduced by 85%.
Source: GlaxoSmithKline
All content and features on this website are copyrighted with all rights reserved. The full details can be found in our privacy statement
